Frontage Shanghai has expanded its early drug discovery services through the acquisition of 70% equity interest in Wuhan Heyan Biomedical Technology Co., Ltd. Heyan Biotech, located in Wuhan Optics Valley, national biotech industry base, provides for target based in vitro pharmacodynamic screening and early pharmacological pharmacodynamic evaluation services in early drug discovery. Technical capabilities include screening of drug targets, customized biological assay development and detection services.
 
“Heyan Biotech mainly provides drug discovery services such as drug activity screening and kinase function test and it has established close research collaborations with many innovative drug companies, well-known universities and scientific research institutes,” said Song Li, chairman and CEO of Frontage. “Its technology platforms as well as talents could effectively complement the existing service lines of Frontage.”
 
Heyan Biotech will focus on expanding the application of SPR technology, Protac technology, ion channels, GPCR targets, intracellular kinase binding evaluation and high connotation technology detection platform. It will cover the fields of neuropathy, metabolic diseases, inflammation, cancer and safety evaluation targets. In addition, Heyan Biotech will expand its service capacity in drug discovery to enhance Frontage’s one-stop service capacity and capability in the field of drug discovery and development.